Skip to main content
メニュー
Revvity logo
Contact us
JP
Revvity Sites Globally

Select your location.

*e-commerce not available for this region.

australia.webp Australia
austria.webp Austria
belgium.webp Belgium
brazil.webp Brazil *
canada.webp Canada
china.webp China *
denmark.webp Denmark
finland.webp Finland
france.webp France
germany.webp Germany
hong-kong.webp Hong Kong (China) *
india.webp India *
ireland.webp Ireland
italy.webp Italy
japan.webp Japan *
luxembourg.webp Luxembourg
mexico.webp Mexico *
netherlands.webp Netherlands
norway.webp Norway
philippines.webp Philippines *
republic of korea.webp Republic of Korea *
singapore.webp Singapore *
spain.webp Spain
sweden.webp Sweden
switzerland.webp Switzerland
thailand.webp Thailand *
uk.webp United Kingdom
usa.webp United States
Breadcrumb
...
  • ホーム
  • Services
  • Revvity Omics Services
  • Revvity Omics Clinical Services
    • Revvity Omics Clinical Services
    • Revvity Omics Pharma Services
  • Proactive Testing
    • Cytogenomics
    • Global Laboratory Network
    • Metabolic Testing
    • Newborn Screening Services
    • Prenatal Screening Services
    • Proactive Testing
    • Rare Disease Testing
    • Specialized and Customized Assays
    • Sponsored Testing Programs
  • Proactive Whole Exome Sequencing
    • Proactive Whole Exome Sequencing
    • Proactive Whole Genome Sequencing
    • Type 1 Diabetes Early Detection

Proactive Whole Exome Sequencing


Early insights. Informed choices. Personalized care for every pregnancy.

Proactive Whole Exome Sequencing

Proactive prenatal whole exome sequencing (WES) provides an early insight into your baby’s genetic health before birth. By analyzing the protein-coding regions of DNA, WES allows for the early detection of rare and inherited conditions that can develop in childhood. This information helps families and healthcare providers make informed decisions and develop personalized prenatal and postnatal care strategies based on the baby's unique genetic profile.

Proactive testing would include sequencing of the nuclear genes of a presumed healthy fetus. Pediatric-onset diagnostic findings will be reported in the selected categories of findings –

  • ACMG Recommended Secondary Findings - pathogenic and likely pathogenic variants in genes recommended for reporting based on well-defined, highly penetrant phenotypes with clinical actionability.
  • Diagnostic findings in all disease-associated genes - pathogenic and likely pathogenic variants are reported in genes associated with disease.

Maternal cell contamination (MCC) is offered as a stand-alone test. It is required for testing of samples derived from amniotic fluid and chorionic villi. MCC studies can be requested on other prenatal/fetal samples at the ordering provider's discretion.

Order testing Test requisition form Contact us
Resources
  • Test requisition form

Testing options

Proactive prenatal testing
STAT Proactive Prenatal Whole Exome Sequencing, DUO
Test Code D1330HE
Turn Around Time 7 - 10 days
Order Test
STAT Proactive Prenatal Whole Exome Sequencing, Proband ONLY
Test Code D1000HE
Turn Around Time 7 - 10 days
Order Test
STAT Proactive Prenatal Whole Exome Sequencing, QUAD
Test Code D1340HE
Turn Around Time 7 - 10 days
Order Test
STAT Proactive Prenatal Whole Exome Sequencing, TRIO
Test Code D1310HE
Turn Around Time 7 - 10 days
Order Test

How to order

Step 1

Test selection and place order

Step 2

Specimen collection and Shipment

Step 3

Sample shipment

Learn more

How to order

Test selection and place order

Select the correct test for your patient, and fill out the appropriate Test requisition form.

  • Please make sure that all sections are completed, and that the patient has signed an informed consent form.
  • If a TRIO is ordered, please feel out the “Familial Information” section for tracking purposes.
Collect a sample

Obtain a sample for testing from the patient using one of the provided Revvity Omics test packs. If you do not have a kit available in your office, please contact us here and we can have one sent out to your office.

  • Ensure that all samples are labeled with the patient name and date of birth.
  • For Trio tests, parental and/or family member samples can be submitted separately from the patient/proband, if needed. Additional samples must be received by the laboratory within three weeks of the original patient/proband submission.
  • All parental/family member samples must be submitted with a fully completed requisition and informed consent form, complete with both physician and patient signatures.
Send a sample

Package the patient sample, informed consent form, and test requisition form back into the test kit, and utilize the included pre-paid shipping label to return the kit to Revvity Omics for processing.

Close

This testing service has not been cleared or approved by the U.S. Food and Drug Administration. Testing services may not be licensed in accordance with the laws in all countries. The availability of specific test offerings is dependent upon laboratory location. The content on this page is provided for informational purposes only, not as medical advice. It is not intended to substitute the consultation, diagnosis, and/or treatment provided by a qualified licensed physician or other medical professionals.

Contact Revvity Omics for more information

Contact us
Revvity Logo

©2025 Revvity - All rights reserved

Revvity is a trademark of Revvity, Inc. All other trademarks are the property of their respective owners.